Hepatology

The results suggest that while MASLD is common in patients with T2DM in primary care, advanced liver disease is rare.

The findings highlight the potential for behavioural strategies, such as dietitian-led interventions, to play a key role in managing liver health.

Results showed that patients receiving the combination therapy experienced a median progression-free survival of 5.8 months, compared with 4.0 months.

This study explored the effects of various metabolic abnormalities, such as central obesity, high blood pressure, and elevated high-sensitivity C-reactive protein (hsCRP), on liver steatosis and fibrosis.

Discover more about strong evidence that public health measures, such as raising alcohol prices and restricting access can significantly reduce alcohol consumption.

Dapagliflozin shows promise for treating MASH, improving liver outcomes without worsening fibrosis in a major trial.

A 2023 global call to action by over 300 experts highlighted the need for clear, cross-specialty care pathways to support earlier identification and referral of people at risk.

In this double-blind, placebo-controlled trial, 181 participants were randomised to receive weekly injections of either 28 mg or 50 mg of efruxifermin or a placebo.